Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | DUT | P33316 | 5/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31653165 | 1.00 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL9548604 | 1.00 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL18877290 | 0.87 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL26135786 | 0.85 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL26136394 | 0.85 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL16647505 | 0.85 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL17533911 | 0.83 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL17534039 | 0.83 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL5189630 | 0.83 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL21063986 | 0.83 | DUT (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499106-A2 | NUCLEOSIDE LINE-1 INHIBITORS | Transposon Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| WO-2023192491-A2 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-3466959-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen BioPharma, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| US-5192749-A | Viricide, AIDS | SYNTEX (U.S.A.) INC. (US) | 1993-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | SLC28A1 159/4885SLC28A2 603/4885SLC29A1 254/4885 |
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | L3MBTL1, TDP1, TRDMT1 | SLC28A1 6/4885SLC28A2 20/4885SLC29A1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.